$8.61
0.8010.24%
Last update: Nov 9, 6:01 AM
Compass Pathways PLC (CMPS) Stock Price, Quote, News & History
CMPSNASDAQ
Compass Pathways surges 11% after COMP360 Phase 3 trial shows durable 52-week relief for treatment-resistant depression.
You can purchase shares of Compass Pathways (NASDAQ:CMPS) through any online brokerage.
Other companies in Compass Pathways’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Compass Pathways has a consensus price target of $21.82.
The stock price for Compass Pathways (NASDAQ: CMPS) is $8.9851 last updated November 9, 2026 at 6:01 AM EST.
There are no upcoming dividends for Compass Pathways.
Compass Pathways does not have any upcoming earnings scheduled.
There is no upcoming split for Compass Pathways.
Compass Pathways is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The...
